Copyright West LLC. Minimum 15 minutes delayed.

News Release

<< Back
Mar 25, 2015

OvaScience to Host Conference Call and Webcast Presentation with IVF Specialists to Review Early AUGMENT Fertility Treatment Patient Experience

Overview of AUGMENT Presentation at Society for Reproductive Investigation Meeting and Select Patient Case Studies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 25, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today a conference call focused on the AUGMENTSM treatment on Friday, March 27, 2015 at 10:00 am ET. The presentation will follow an AUGMENT treatment presentation at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting, which represents the first time detailed clinical experience will be presented.

Company management will be joined by two leading in vitro fertilization (IVF) specialists among the first to use the AUGMENT treatment in clinical practice. Robert Casper, M.D., F.R.C.S.(C), Medical Director of TCART Fertility Partners in Toronto, Canada, and Kutluk Oktay, M.D., F.A.C.O.G, of Gen-art IVF in Ankara, Turkey, will present initial AUGMENT experience from their respective clinics, including select patient case studies. The AUGMENT treatment is not available in the United States.

A live, listen-only presentation can be accessed via webcast by visiting the Investors section of the Company’s website at The call can be accessed by dialing (877) 930-8299 (U.S.) or (253) 336-8765 (international) five minutes prior to the start of the call and providing the passcode 14733732. A replay of the webcast will be archived on the Company’s website for two weeks following the event.

About OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit and and connect with us on Twitter and Facebook.

Forward-Looking Statements
This press release includes forward-looking statements about the Company’s business and development plans for the AUGMENT treatment and its two fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.


Source: OvaScience

Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer
Cara Mayfield, 617-714-9638
Director, Corporate Communications